Screen Shot 2020-09-16 at 1.45.20 PM.png

Prothelia is a preclinical-stage biopharmaceutical company focused on the development of novel therapeutic proteins to treat rare muscle diseases with extremely high unmet need.

Prothelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficiency or LAMA2 deficiency.

© 2020 LabShares Newton

Address:

90 BRIDGE STREET

NEWTON, MA 02458

Phone:

617-396-4329

Email:

info@labshares.com

Please note: Phone number is for lab space inquiries. Other inquiries should be directed via email to info@labshares.com

Follow us on social media:

  • LinkedIn
  • Twitter
  • Facebook
  • YouTube
  • Pinterest
  • Yelp
  • Reddit logo
  • Quora logo